Grandfield & Dodd’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
IA
VCM
VAM
Grandfield & Dodd's AZN Position: Q1 2026 in Review
Grandfield & Dodd reduced its AstraZeneca (AZN) stake by 2.1% in Q1 2026, selling an estimated $13.1K and leaving 3,144 shares worth $620K. The position accounts for 0.04% of the portfolio, ranked #132.
Grandfield & Dodd first reported a position in AZN in Q3 2021 and has held it in 19 quarters since. The position peaked at $870K in Q2 2022. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.
- Grandfield & Dodd held 3,144 shares of AstraZeneca worth $620K as of Q1 2026.
- Grandfield & Dodd sold 68 AstraZeneca shares in Q1 2026, an estimated $13.1K.
- AstraZeneca made up 0.04% of Grandfield & Dodd's portfolio in Q1 2026, its #132 holding.
- Grandfield & Dodd first reported a position in AstraZeneca in Q3 2021 and has held it in 19 quarters since.
- Grandfield & Dodd's AstraZeneca position peaked at $870K in Q2 2022.
- 1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.
Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.